Aspen Neuroscience, a clinical-stage biotechnology company developing stem cell therapies for Parkinson’s disease, has announced terms for a proposed $150 million initial public offering (IPO). The San Diego-based company plans to offer 9.4 million shares at a price range of $15 to $17 per share, implying a fully diluted market value of approximately $494 million at the midpoint.
Company Background
Founded in 2018, Aspen Neuroscience is developing autologous induced pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases. Its approach uses cells derived from a patient’s own tissue to develop potential treatments.
The company’s lead candidate, sasineprocel, is a single-dose cell therapy manufactured from cells collected through a patient’s skin biopsy. It is designed to replace dopaminergic neurons lost in Parkinson’s disease, targeting a key feature of the condition.
IPO Details
Aspen Neuroscience plans to raise $150 million by offering approximately 9.4 million shares at $15 to $17 each. At the midpoint of the proposed range, the company would have a fully diluted market value of approximately $494 million.
The company intends to list on the Nasdaq under the ticker symbol ASPE. Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, and Oppenheimer & Co. are serving as joint bookrunners. The offering was expected to price during the week of October 26, 2026.
Clinical Development and Regulatory Progress
Aspen Neuroscience is evaluating sasineprocel in an open-label Phase 1/2a clinical trial. As of August 18, 2026, 15 patients had received the treatment.
Following feedback from the US Food and Drug Administration (FDA), the company anticipates dosing patients in a Phase 3 trial during the second half of 2027. Sasineprocel has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA.
These designations provide regulatory pathways intended to facilitate the development and review of qualifying therapies. They do not establish that sasineprocel is effective or guarantee approval.
Market Context and Opportunities
Aspen Neuroscience’s proposed IPO would provide a public-market financing opportunity for a company focused on cell-based treatment for Parkinson’s disease. Its autologous approach and planned progression toward Phase 3 testing are central elements of its development strategy.
The potential transition to a later-stage trial would represent an important step in evaluating the therapy, although the available information does not disclose the company’s planned use of IPO proceeds, current cash reserves, or expected clinical development costs.
Risks and Challenges
Sasineprocel remains investigational, and the reported enrollment of 15 patients does not establish its safety or efficacy. Further clinical testing will be required to evaluate treatment outcomes and determine whether the therapy can support a regulatory application.
The anticipated Phase 3 timeline is also dependent on clinical and regulatory progress. As with other clinical-stage biotechnology companies, Aspen Neuroscience faces the costs and uncertainty associated with advancing a treatment through later-stage trials.
Closing Insights
Aspen Neuroscience’s proposed $150 million IPO would support a clinical-stage company developing an autologous stem cell therapy for Parkinson’s disease. Sasineprocel’s progress through Phase 1/2a testing and the company’s anticipated Phase 3 start in the second half of 2027 are key milestones to watch. The investment case remains tied to future clinical evidence, regulatory progress, and the company’s ability to advance its lead candidate.
